Oryzon Genomics SA (ORY) - Financial Analysis Review - GlobalData - Company Reports

Oryzon Genomics SA (ORY) - Financial Analysis Review

Oryzon Genomics SA (ORY) - Financial Analysis Review - GlobalData - Company Reports
Oryzon Genomics SA (ORY) - Financial Analysis Review
Published Nov 29, 2016
35 pages — Published Nov 29, 2016
Price US$ 125.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Oryzon Genomics SA (Oryzon) is a clinical stage biopharmaceutical company that offers development of epigenetics-based therapeutics. The company offers epigenetics, a regulatory system that controls gene expression without affecting the makeup of the genes themselves and provides regulation of gene transcription that has emerged as a key biological determinant of protein production and cellular differentiation. It provides therapeutic programs and collaborative research services. The company offers therapeutic programs for patients with cancers or neurodegenerative disorders. It offers genomics services to the pharmaceutical industry in Europe.

GlobalData's Oryzon Genomics SA (ORY) - Financial Analysis Review provides a comprehensive insight into the company's history, business structure and operations. The report contains information on the company's key employees, key competitors and major products and services, as well as detailed financial ratios for the last 5 years.

Oryzon Genomics SA Key Recent Developments:

Oct 24,2016: ORYZON Reports Financial Results and Corporate Update for the 3rd Quarter Ended September 30, 2016
Aug 08,2016: Oryzon Reports Financial Results and Corporate Update for the 1st Half Ended June 30, 2016
May 12,2016: Oryzon Reports First Quarter 2016 Financial Results and Corporate Update
Jan 26,2016: Oryzon Genomics to Present at the Epigenetics in Drug Discovery Workshop
Dec 10,2015: Oryzon Genomics Announces Listing on Madrid Stock Exchange


This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope
- Business description - A detailed description of the company's operations and business divisions.
- Company history - Progression of key events associated with the company.
- Major products and services - A list of major products, services and brands of the company.
- Key competitors - A list of key competitors to the company.
- Key employees - A list of the key executives of the company.
- Executive biographies - A brief summary of the executives' employment history.
- Key operational heads - A list of personnel heading key departments/functions.
- Important locations and subsidiaries - A list of key locations and subsidiaries of the company, including contact details.
- Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note: Some sections may be missing if data is unavailable for the company.

Reasons to Buy

- Gain key insights into the company for academic or business research purposes. Key elements such as detailed business description and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
- Identify potential customers and suppliers with this report's analysis of the company's business structure, operations, major products and services.
- Examine potential investment and acquisition targets with this report's detailed insight into the company's business, financial and operational performance. Financial ratios presented for major public companies in the report include; revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

  
Source:
Document ID
GDME104712FA
Country
Industry
Ticker
ORY=ES
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents23
  List of Tables31
  List of Figures41
Section 1 - About the Company41
Oryzon Genomics SA - Key Facts51
Oryzon Genomics SA - Key Employees61
Oryzon Genomics SA - Major Products and Services71
Oryzon Genomics SA - Medical Equipment Pipeline Products Data83
  Oryzon Genomics SA Pipeline Products by Equipment Type81
  Oryzon Genomics SA Pipeline Products by Development Stage92
Oryzon Genomics SA - History111
Oryzon Genomics SA - Locations And Subsidiaries121
  Head Office121
  Other Locations &Subsidiaries121
  Joint Venture121
Section 2 Company Analysis131
Company Overview131
Oryzon Genomics SA - Key Competitors141
Section 3 Company Financial Ratios151
Financial Ratios - Capital Market Ratios151
Financial Ratios - Annual Ratios162
Performance Chart181
Financial Performance181
Financial Ratios - Interim Ratios191
Financial Ratios - Ratio Charts201
Section 4 Company s Lifesciences Financial Deals and Alliances212
  Oryzon Genomics SA, Pharmaceuticals &Healthcare, Deals By Year, 2010 to YTD 2016211
  Oryzon Genomics SA, Pharmaceuticals &Healthcare, Deals By Type, 2010 to YTD 2016221
Oryzon Genomics SA, Recent Deals Summary231
Section 5 Company s Recent Developments241
Oct 24, 2016: ORYZON Reports Financial Results and Corporate Update for the 3rd Quarter Ended September 30, 2016241
Aug 08, 2016: Oryzon Reports Financial Results and Corporate Update for the 1st Half Ended June 30, 2016251
May 12, 2016: Oryzon Reports First Quarter 2016 Financial Results and Corporate Update261
Jan 26, 2016: Oryzon Genomics to Present at the Epigenetics in Drug Discovery Workshop271
Dec 10, 2015: Oryzon Genomics Announces Listing on Madrid Stock Exchange281
Nov 04, 2015: ORYZON Announces the Appointment of Mr. Antonio Fornieles, Ms. Isabel Aguilera and Mr. Ramon Adell as Independent Directors291
Sep 17, 2015: Oryzon Shareholders Approve Listing to the Spanish Continuous Market301
Section 6 Appendix315
  Methodology311
  Ratio Definitions314
  About GlobalData351
  Contact Us351
  Disclaimer351

Table Of Contents

GlobalData - Company Reports—GlobalData is an industry analysis specialist, providing business information products and services. These high quality company reports are created via a large research and analysis capability, drawing from extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
GlobalData - Company Reports. "Oryzon Genomics SA (ORY) - Financial Analysis Review" Nov 29, 2016. Alacra Store. Jun 26, 2019. <http://www.alacrastore.com/storecontent/GlobalData-Company-Reports/Oryzon-Genomics-SA-ORY-Financial-Analysis-Review-2087-64328>
  
APA:
GlobalData - Company Reports. (2016). Oryzon Genomics SA (ORY) - Financial Analysis Review Nov 29, 2016. New York, NY: Alacra Store. Retrieved Jun 26, 2019 from <http://www.alacrastore.com/storecontent/GlobalData-Company-Reports/Oryzon-Genomics-SA-ORY-Financial-Analysis-Review-2087-64328>
  
US$ 125.00
$  £  
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Company Profiles from one place.